A clear transdermal cannabinoid (CBD) gel (ZYN002, Zynerba Pharmaceuticals) improved key symptoms of fragile X syndrome in the phase 2 FAB-C … Read More
The post Positive Topline Results for Cannabinoid Gel in Fragile X appeared first on Dagga Magazine.